Show simple item record

dc.contributor.authorJimenez-Sousa, Maria Angeles 
dc.contributor.authorFernandez-Rodriguez, Amanda 
dc.contributor.authorHeredia, María
dc.contributor.authorTamayo, Eduardo
dc.contributor.authorGuzman-Fulgencio, Maria 
dc.contributor.authorLajo, Carmen
dc.contributor.authorLópez, Elisabeth
dc.contributor.authorGómez-Herreras, José I
dc.contributor.authorBustamante, Jesús
dc.contributor.authorBermejo-Martín, Jesús F
dc.contributor.authorResino, Salvador 
dc.date.accessioned2024-01-19T12:58:59Z
dc.date.available2024-01-19T12:58:59Z
dc.date.issued2012-06
dc.identifier.citationCytokine. 2012 Jun;58(3):321-6.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17239
dc.description.abstractBackground: Persistent inflammation and fibrosis have been related to active progression of renal deterioration and reduced survival of kidney transplant. The aim of this study was to determine the impact of single-nucleotide polymorphisms (SNPs) located in regions related to inflammatory and immune processes on the development of chronic renal allograft dysfunction (CRAD). Methods: A retrospective study was carried out on 276 patients who received kidney transplant (KT). SNPs were genotyped via the SNPlex platform. Statistical analysis was performed with SNPstat and regression logistic analyses were adjusted by age and gender of recipients and donors, cold ischemia time and the number of human leukocyte antigen (HLA) mismatches. Results: From 276 patients with KT, 118 were non-CRAD and 158 were CRAD. Three SNPs showed significant associations with CRAD development: rs1800471 in transforming growth factor beta 1 (TGFB1), rs5186 in angiotensin II receptor type 1 (AGTR1), and rs699947 in vascular endothelial growth factor A (VEGFA). GC genotype of rs1800471 was associated with increased odds of CRAD compared to GG genotype (OR=2.65 (95% confidence interval (CI)=1.09; 6.47), p=0.025), as well as AC and AA genotype of rs699947 assuming a dominant model (OR=1.80 (95% CI=1.02; 3.20), p=0.044). Besides, AC and CC genotypes of rs5186 were associated with reduced odds of CRAD assuming a dominant model (OR=0.56 (95% CI=0.33; 0.96), p=0.033). Conclusion: Our findings suggest that three genes related to immunity and inflammation (rs1800471, rs5186 and rs699947) are associated to susceptibility or protection to CRAD, and might have diagnostic utility in predicting the likelihood of developing CRAD.es_ES
dc.description.sponsorshipThis work was supported by two Grants from Instituto de Salud Carlos III (Ref: PI08/0738 and PI11/00245) and from Junta de Castilla y León (Ref: GRS 234/A/08). MAJs, AFR and MGF are supported by Grants from Instituto de Salud Carlos III, CM10/00105, UIPY-1377/08 and CM09/00031, respectively.es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionAMes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectKidney transplantes_ES
dc.subjectAllograft rejectiones_ES
dc.subjectSNPses_ES
dc.subjectGrow factorses_ES
dc.subjectBiomarkerses_ES
dc.subject.meshKidney Transplantation es_ES
dc.subject.meshPolymorphism, Single Nucleotidees_ES
dc.subject.meshAdult es_ES
dc.subject.meshAged es_ES
dc.subject.meshFemale es_ES
dc.subject.meshGraft Rejection es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshReceptor, Angiotensin, Type 1es_ES
dc.subject.meshRetrospective Studies es_ES
dc.subject.meshTransforming Growth Factor beta1 es_ES
dc.subject.meshTransplantation, Homologous es_ES
dc.subject.meshVascular Endothelial Growth Factor A es_ES
dc.titleGenetic polymorphisms located in TGFB1, AGTR1, and VEGFA genes are associated to chronic renal allograft dysfunctiones_ES
dc.typeresearch articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID22433249es_ES
dc.format.volume58es_ES
dc.format.number3es_ES
dc.format.page321-326es_ES
dc.identifier.doi10.1016/j.cyto.2012.02.017es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderJunta de Castilla y León (España) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1096-0023es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.cyto.2012.02.017es_ES
dc.identifier.journalCytokinees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MICINN//PI11%2F00245/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MICINN//CM10%2F00105/ES/CM10%2F00105/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MICINN//CM09%2F00031/ES/CM09%2F00031/ es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI08/0738es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/UIPY-1377/08es_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional